U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H18ClN3O4S2
Molecular Weight 379.8853
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPENTHIAZIDE

SMILES

C1CCC(C1)CC2Nc3cc(c(cc3S(=O)(=O)N2)S(=O)(=O)N)Cl

InChI

InChIKey=BKYKPTRYDKTTJY-UHFFFAOYSA-N
InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)

HIDE SMILES / InChI

Molecular Formula C13H18ClN3O4S2
Molecular Weight 379.8853
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Cyclopenthiazide is a thiazide diuretic. It inhibits the Na+-Cl− symporter in the distal convoluted tubule of the kidney. Cyclopenthiazide is used for the treatment of edema, including that associated with heart failure, and for the treatment of hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P55017
Gene ID: 6559.0
Gene Symbol: SLC12A3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
Primary
NAVIDREX

Approved Use

Navidrex® 0.5mg Tablets are used to treat high blood pressure and some types of heart problems. They are also used to help reduce fluid retention associated with the pre-menstrual syndrome and some kidney or liver diseases.
PubMed

PubMed

TitleDatePubMed
Effect of long-term diuretic treatment on body-potassium in heart-disease.
1976 Nov 13
Is nifedipine a suitable first-line treatment for essential hypertension in general practice?
1987 Nov

Sample Use Guides

In Vivo Use Guide
The usual adult dose is half of one tablet (0.25 mg) , or one whole tablet (0.5 mg) a day, alone or with other medicines.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:38:18 UTC 2021
Edited
by admin
on Sat Jun 26 15:38:18 UTC 2021
Record UNII
VX4S2N85F5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLOPENTHIAZIDE
INN   JAN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
CYCLOPENTHIAZIDE [MI]
Common Name English
CYCLOPENTHIAZIDE [INN]
Common Name English
6-CHLORO-3-(CYCLOPENTYLMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
Systematic Name English
CYCLOPENTHIAZIDE [JAN]
Common Name English
SU-8341
Code English
CYCLOPENTHIAZIDE [USAN]
Common Name English
CYCLOPENTHIAZIDE [WHO-DD]
Common Name English
NSC-107679
Code English
NAVIDREX
Brand Name English
CYCLOPENTHIAZIDE [MART.]
Common Name English
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3-(CYCLOPENTYLMETHYL)-3,4-DIHYDRO-, 1,1-DIOXIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C49185
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-VATC QC03AA07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-VATC QC03AB07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-ATC C03EA07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-ATC C03AA07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-VATC QC03EA07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
WHO-ATC C03AB07
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
Code System Code Type Description
IUPHAR
7899
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
EPA CompTox
742-20-1
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
INN
1230
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
FDA UNII
VX4S2N85F5
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
ChEMBL
CHEMBL1373254
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
DRUG BANK
DB13532
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
MERCK INDEX
M4010
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY Merck Index
EVMPD
SUB06857MIG
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
NCI_THESAURUS
C80839
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
PUBCHEM
2904
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
WIKIPEDIA
CYCLOPENTHIAZIDE
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
CAS
742-20-1
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
DRUG CENTRAL
756
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
MESH
D003518
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
ECHA (EC/EINECS)
212-012-5
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY
RXCUI
3000
Created by admin on Sat Jun 26 15:38:18 UTC 2021 , Edited by admin on Sat Jun 26 15:38:18 UTC 2021
PRIMARY RxNorm
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
DEGRADENT -> PARENT
Related Record Type Details
ACTIVE MOIETY